Thursday 12 November 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY

Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue: +14.0%
EPS: −277.9%
Free cash flow: −233.0%
Total debt: −10.5%

Quarter to September 2026, against a year earlier

121.89 0.38 −0.31%

Follow INCY

Alert me

Market cap: $24.9B
P/E: 58.1×
Fwd P/E: 57.3×
Dividend yield: —
F-score: 9/9
ROIC: 21.6%
Net debt / EBITDA: −2.2×
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Incyte Corporation (INCY) Price to free cash flow

Alert me on Price to free cash flow

As of 12 November 2026, Incyte Corporation (INCY) trades at a price to free cash flow of 36.4×. Over the past ten years it has ranged from 0.0× (September 2024) to 956× (November 2024); the current reading is higher than 66% of that period. That is above the Biotechnology industry median of 26.1× and above the Healthcare sector median of 20.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/INCY/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Incyte Corporation price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/INCY/metrics/price-to-free-cash-flow">Incyte Corporation (INCY) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	14.5×	(76.16%)
FY2024	60.8×	86.60%
FY2023	32.6×	64.67%
FY2022	19.8×	(30.44%)
FY2021	28.5×	—
FY2020	0.0×	—
FY2019	29.7×	(42.29%)
FY2018	51.4×	—
FY2017	0.0×	—
FY2016	104×	(66.08%)

Period	Price to free cash flow	Change
Sep 2026	36.3×	201.92%
Jun 2026	12.0×	(9.01%)
Mar 2026	13.2×	(8.94%)
Dec 2025	14.5×	2.41%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 956×

Ten-year median 26.6×

Current reading's percentile 66

Company	Price to free cash flow
ROIV Roivant Sciences Ltd. compare	n/m
INSM Insmed, Inc. compare	n/m
BNTX BioNTech SE Sponsored ADR compare	n/m
GMAB Genmab A/S Sponsored ADR compare	n/m
JAZZ Jazz Pharmaceuticals PLC compare	10.3×
EXEL Exelixis, Inc. compare	15.1×
ALNY Alnylam Pharmaceuticals, Inc. compare	26.1×
INCY Incyte Corporation	36.4×
ASND Ascendis Pharma A/S compare	44.5×
Biotechnology industry median	26.1×
Healthcare sector median	20.5×
Market median	13.9×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Incyte Corporation (INCY) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on INCY

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on INCY

Stockrow Weekly